Zeng Da-Xiong, Wang Chang-Guo, Huang Jian-An, Jiang Jun-Hong
Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Onco Targets Ther. 2017 Aug 28;10:4269-4272. doi: 10.2147/OTT.S139520. eCollection 2017.
Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer. In this study, we show the result of apatinib as salvage treatment in lung adenocarcinoma patients with KRAS mutation. Four advanced lung adenocarcinoma patients with KRAS mutation were orally administered apatinib (250 mg/d) after second-line treatment. One patient showed progressive disease, while 3 patients showed stable disease response to apatinib, with a median progression-free survival (PFS) of 3.8 months (1.5-5.5 months). The main toxicities were hoarseness and hemoptysis, which were manageable. Therefore, apatinib might be an optional choice for advanced lung adenocarcinoma patients with KRAS mutation in post second-line treatment.
肺腺癌中激活的KRAS突变具有治疗耐药性和预后不良的特点。作为血管内皮生长因子受体-2（VEGFR-2）酪氨酸激酶的小分子抑制剂，阿帕替尼已在晚期胃癌和乳腺癌中取得成功。在本研究中，我们展示了阿帕替尼作为KRAS突变的肺腺癌患者挽救治疗的结果。4例KRAS突变的晚期肺腺癌患者在二线治疗后口服阿帕替尼（250mg/d）。1例患者出现疾病进展，而3例患者对阿帕替尼表现出疾病稳定反应，中位无进展生存期（PFS）为3.8个月（1.5 - 5.5个月）。主要毒性为声音嘶哑和咯血，这些毒性是可控的。因此，阿帕替尼可能是二线治疗后KRAS突变的晚期肺腺癌患者的一个可选选择。
